Alphamab inks Sanofi collaboration on novel cancer therapy
In another U.S.-China deal, Jiangsu Alphamab Biopharma, a subsidiary of Alphamab Oncology, has partnered with Sanofi to co-develop its HER2-positive breast cancer treatment as it enters mid-stage clinical trials.
KN026 is an antibody that binds to two sites, or epitopes, on HER2, a type of protein that is up-regulated in HER2-positive breast cancer. The dual-binding blocks the activation of HER2 signaling pathway.
Alphamab’s clinical trial will investigate KN026’s effectiveness in treating patients with metastatic, HER2-positive breast cancer, either as a monotherapy or in combination with Sanofi’s chemotherapy agent Taxotere, otherwise known as docetaxel.
The Phase 2 study is currently recruiting patients and is estimated to complete towards the end of 2021, records on clinicaltrials.gov showed.
KN026 is an antibody that binds to two sites, or epitopes, on HER2, a type of protein that is up-regulated in HER2-positive breast cancer. The dual-binding blocks the activation of HER2 signaling pathway.
Alphamab’s clinical trial will investigate KN026’s effectiveness in treating patients with metastatic, HER2-positive breast cancer, either as a monotherapy or in combination with Sanofi’s chemotherapy agent Taxotere, otherwise known as docetaxel.
The Phase 2 study is currently recruiting patients and is estimated to complete towards the end of 2021, records on clinicaltrials.gov showed.
.png)
No hay comentarios:
Publicar un comentario